Bristol Sweetens ImClone Bid A Bit, Plans To Ask Stockholders To Replace Board
This article was originally published in The Pink Sheet Daily
Executive Summary
BMS ups ante by $2 per share, for a total $4.7 billion cash offer.
You may also be interested in...
Lilly’s ImClone Buy Adds Oncology Candidates And Pipeline Pressures
Eli Lilly announced Oct. 6 that it is acquiring ImClone for $6.5 billion, confirming rumors that had been circulating since the middle of the previous week. The central question now is whether Lilly can turn the buyout into a win for shareholders
Lilly’s ImClone Buy Adds Oncology Candidates And Pipeline Pressures
Eli Lilly announced Oct. 6 that it is acquiring ImClone for $6.5 billion, confirming rumors that had been circulating since the middle of the previous week. The central question now is whether Lilly can turn the buyout into a win for shareholders
Lilly Snatches ImClone Away From Bristol
Lilly’s $6.5 billion acquisition of ImClone will create an oncology “powerhouse” with 18 cancer drugs in clinical development.